China SXT Pharmaceuticals Secures $760K in Highly Dilutive Offering at Deep Discount
SXTC sits 78% above its 52-week low of $1.25.
Summary
China SXT Pharmaceuticals completed a direct offering of 2 million shares at $0.38 per share, raising $760,000, which is highly dilutive and priced at a deep discount to recent market prices.
Key Events · Financing and Capital Events · SXTC
-
Direct Offering Completed
The company sold 2,000,000 Class A Ordinary Shares directly to investors through a securities purchase agreement dated April 7, 2026.
-
Significant Capital Raised
The offering generated aggregate gross proceeds of $760,000 for the company.
-
Deep Discount Pricing
Shares were sold at $0.38 per share, an approximate 81% discount compared to the last reported sale price of $2.07 on April 7, 2026.
-
Substantial Share Dilution
The 2,000,000 new shares represent over 200% of the 958,077 Class A Ordinary Shares outstanding immediately before the offering, significantly diluting existing shareholders.
Analysis · SXTC · Life Sciences
China SXT Pharmaceuticals has completed a direct offering of 2,000,000 Class A Ordinary Shares, generating gross proceeds of $760,000. This offering is highly dilutive, representing over 200% of the shares outstanding immediately prior to the transaction. The shares were sold at $0.38 each, an approximate 81% discount to the last reported sale price of $2.07 on April 7, 2026. The substantial discount and significant dilution indicate a pressing need for capital, which could negatively impact existing shareholders. Proceeds are earmarked for general corporate purposes and working capital.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTC was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.25 to $1,046.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.